Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
GLP-1 Receptor Agonist-Induced Loss and Impairment of Muscle Mass - Evaluation of Response
University of Alberta
50 participants
Apr 14, 2026
OBSERVATIONAL
Conditions
Summary
The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.
Eligibility
Inclusion Criteria3
- Adults 18-80 years of age
- Starting semaglutide for type 2 diabetes or weight loss
- Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)
Exclusion Criteria4
- Current use of semaglutide for more than 2 weeks
- Major recent heart issues or other severe health conditions
- Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
- Dependence on a mobility aid (unable to participate in exercise MRI)
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07272837